KCNK2 and depressive symptom measurement: Accordingly, Trek1 represents a potential target for novel therapeutic strategies to combat depression (Perlis et al., 2008; Liou et al., 2009; Mazella et al., 2010; Moha ou Maati et al., 2011; Moha Ou Maati et al., 2012).